Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
pharmaceutical investing Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
NevGold Releases Some of the Highest Grade Oxide Gold-Antimony Results To Date: 9.68 g/t AuEq Over 11.6 Meters Within 2.85 g/t AuEq Over 60.3 Meters at the Limousine Butte Project, Nevada
